DRS

Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando, Florida.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando, Florida.
  • Mirum will host a scientific symposium, Beyond Itch: Exploring the Clinical Benefits of Treating Cholestasis in Children, featuring Drs.
  • The event will take place on Thursday, October 13, 2022 from 7:15-8:45pm ET in Sebastian L 1/2.
  • LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.

High-frequency Electrical Stimulation Helps Reduce Inflammation, Pain in New Feinstein Institutes Study

Retrieved on: 
Wednesday, October 5, 2022

And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.

Key Points: 
  • And while pain is an important defense mechanism to protect the body and promote healing, chronic pain can be debilitating.
  • The research, led by Feinstein Institutes Sangeeta Chavan, PhD , showed in preclinical mice models that HFES inhibits neuroinflammatory mediator release by sensory neurons, called nociceptors, to reduce pain.
  • For your body to feel pain, neurons release molecules that kickstart the bodys immune response causing inflammation and pain.
  • We now have a better understanding as to why high-frequency stimulation helps attenuate inflammation and associated pain.

Virtual Reality Experience to Help Ease Pediatric Patient Anxiety Developed by Before Inc. and Saritasa

Retrieved on: 
Wednesday, October 5, 2022

NEWPORT BEACH, Calif., Oct. 5, 2022 /PRNewswire/ -- Saritasa Technology Solutions, innovation partners delivering new products and solutions to clients, and Before, Inc., have released a new virtual reality (VR) software prototype to get children comfortable with medical procedures before surgery. The unique VR experience gives children and young teenagers a chance to familiarize themselves with medical tools in a safe environment ahead of their medical procedure to relieve preoperative anxiety.

Key Points: 
  • Before Inc. provides products and services to help acclimate and mentally prepare patients and their families for medical procedures.
  • The degree of anxiety before a medical procedure varies but Pediatric Health, Medicine and Therapeutics reports that several studies indicate that 50% to 75% of pediatric patients suffer from preoperative stress.
  • Before, Inc. is developing its first product with Saritasa, a virtual reality perioperative walkthrough for pediatric patients and their families to reduce preoperative anxiety.
  • Saritasa specializes in custom software development, mobile development, augmented reality and virtual reality development, IoT solutions, web, database development, and DevOps.

STEER Technologies Inc. Receives TSXV Approval to Finalize Corporate Name Change

Retrieved on: 
Wednesday, October 5, 2022

Facedrive Inc. (STEER or the Company) (TSXV: FD) (OTCQX: FDVRF), an integrated ESG technology platform, is pleased to announce it has received TSX Venture Exchange (the TSXV) approval for its corporate name change from Facedrive Inc. to STEER Technologies Inc. and its related stock symbol change to STER.

Key Points: 
  • Facedrive Inc. (STEER or the Company) (TSXV: FD) (OTCQX: FDVRF), an integrated ESG technology platform, is pleased to announce it has received TSX Venture Exchange (the TSXV) approval for its corporate name change from Facedrive Inc. to STEER Technologies Inc. and its related stock symbol change to STER.
  • This announcement follows on the Companys news release dated April 20, 2022, announcing its overall rebranding efforts to STEER and the approval of its shareholders to a corporate name change on July 12, 2022.
  • Trading on the TSXV in the Companys common shares under the new ticker symbol STER will commence at market opening on October 11, 2022.
  • There is no change in the capitalization of the Company in connection with the change of name and new trading symbols.

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer

Retrieved on: 
Tuesday, October 4, 2022

to Chief Executive Officer.

Key Points: 
  • to Chief Executive Officer.
  • Mr. Loiacono has played a key role as Chief Business Officer at BlueSphere over the last year, working closely with co-founders Drs.
  • Mark and Warren Shlomchik, Dr. Bob Keefe, Chief Development Officer, and the broader team at BlueSphere.
  • Mr. Loiacono will lead BlueSphere into the next phase of growth, as the company continues to build out its clinical and research activities.

Unifeye Vision Partners Expands into North Dakota

Retrieved on: 
Tuesday, October 4, 2022

DALLAS, Oct. 4, 2022 /PRNewswire/ -- Unifeye Vision Partners ("UVP"), a leading network of comprehensive eye care providers, today announced the completion of a strategic partnership with Northern Plains Surgery Center, based in Fargo, North Dakota. This represents UVP's fifth practice within the Upper Midwest and the 13th member of the growing UVP community.

Key Points: 
  • DALLAS, Oct. 4, 2022 /PRNewswire/ -- Unifeye Vision Partners ("UVP"), a leading network of comprehensive eye care providers, today announced the completion of a strategic partnership with Northern Plains Surgery Center, based in Fargo, North Dakota.
  • Founded in 1999 by physician partners including Dr. Steven Bagan and Dr. Lance Bergstrom (who remain physician partners today), the Northern Plains Surgery Center serves physicians and patients from Bagan Strinden Vision, Eye Consultants of North Dakota, and Bergstrom Eye and Laser Clinic.
  • "We are excited to extend our substantial presence in the Twin Cities of Minnesota into the North Dakota market," said Martin Rash, CEO of Unifeye Vision Partners.
  • Unifeye Vision Partners was formed to partner with leading eye care providers in targeted markets throughout the United States.

FPA Partners with Psychology of Financial Planning Specialist Certificate Program to Support FPA Members

Retrieved on: 
Monday, October 3, 2022

In response, the Financial Planning Association (FPA) announced today a new partnership to offer members access to the Psychology of Financial Planning Specialist Badge.

Key Points: 
  • In response, the Financial Planning Association (FPA) announced today a new partnership to offer members access to the Psychology of Financial Planning Specialist Badge.
  • The Psychology of Financial Planning Specialist Badge Program is an on-demand program for financial planners with over 7 hours of video instruction and exercises.
  • Upon completion of the program, financial planners will receive the Psychology of Financial Planning Specialist Badge, which they can display on their websites and social media platforms.
  • The Financial Planning Association (FPA) is the leading membership organization and trade association for Certified Financial PlannerTM professionals and those engaged in the financial planning process.

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

Retrieved on: 
Monday, October 3, 2022

The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.

Key Points: 
  • The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.
  • The results favored ultrafiltration over diuretics in reducing heart failure events within 30 days and cardiovascular mortality within 90 days.
  • Adjustable Ultrafiltration (AUF) was statistically superior compared to Adjustable IV Loop Diuretics (ALD) with 81% more wins (Win Ratio=1.81, p=0.0429).
  • Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics.

Solarea Bio Investigators Receive National Academy of Medicine Healthy Longevity 2022 Quickfire Challenge Award

Retrieved on: 
Thursday, September 29, 2022

CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- Solarea Bio, a clinical stage biotech company, has been selected as an awardee of the NAM Healthy Longevity 2022 QuickFire Challenge, launched by Johnson & Johnson Innovation together with the National Academy of Medicine, for work studying the mycobiome as a novel class of probiotics to target inflammation associated with aging, or 'inflammaging'.  

Key Points: 
  • CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- Solarea Bio , a clinical stage biotech company, has been selected as an awardee of the NAM Healthy Longevity 2022 QuickFire Challenge, launched by Johnson & Johnson Innovation together with the National Academy of Medicine, for work studying the mycobiome as a novel class of probiotics to target inflammation associated with aging, or 'inflammaging'.
  • With inflammation as its core target, Solarea is developing a pipeline of products in addition to its existing lead clinical program for the dietary management of bone health.
  • Dr. Eric Schott, co-founder and Vice President of Translational Research and Operations at Solarea said, "Healthy aging as a target is advancing through the product development process with strong initial results.
  • The National Academy of Medicine's Healthy Longevity Initiative is designed to kick start innovation to support healthy longevity through a series of monetary awards and prizes.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.